1007570-12-8

Basic information

• Product Name: O-(4-bromophenyl)hydroxylamine hydrochloride
• Synonyms: O-(4-bromophenyl)hydroxylamine hydrochloride
• CAS NO: 1007570-12-8
• Molecular Weight: 224.485
• Mol File: 1007570-12-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: O-(4-bromophenyl)hydroxylamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: O-(4-bromophenyl)hydroxylamine hydrochloride(1007570-12-8)
• EPA Substance Registry System: O-(4-bromophenyl)hydroxylamine hydrochloride(1007570-12-8)

Safety Data

• Hazardous Substances Data: 1007570-12-8(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 65440-82-6 O-(4-bromophenyl)hydroxylamine 

Downstream Products

• 880472-29-7 C₁₆H₁₃BrClF₃N₂O₃S 
• 28718-83-4 5-bromo-2-(4-bromo-phenyl)-3-methyl-benzofuran 
• 1387002-79-0 tert-butyl 8-(3-fluorophenylsulfonyl)-3,4-dihydrobenzofuro[3,2-c]pyridine-2(1H)-carboxylate 
• 1627150-06-4 (2E,4E)-4-[(4-bromophenoxy)imino]-2-butenoic acid 2,3,4,5,6-pentafluorophenyl ester 
• 1627150-22-4 C₁₂H₁₂BrNO₃ 
• 1019995-51-7 C₁₆H₁₃BrN₂O₂ 

Relevant articles and documents

Synthesis of Functionalized 2-(4-Hydroxyphenyl)-3-methylbenzofuran Allosteric Modulators of Hsp90 Activity

Hsp90 is a molecular chaperone that plays a pivotal role in the cell life cycle. ATP-regulated internal dynamics are critical to Hsp90 function and we recently demonstrated that these dynamics can be modulated in an allosteric fashion; the protein C-terminal domain (CTD) can be effectively targeted with a family of 2-phenyl-benzofuran derivatives. Here we describe the expansion of the initial library, reporting 28 new derivatives that explore the chemical space at opposite ends of the benzofuran scaffold. Interactions of the compounds with a full-length protein homolog were explored by Saturation Transfer Difference (STD) NMR spectroscopy. In this context we also report the interaction epitope of Novobiocin, a known CTD inhibitor.

BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA

The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, methods of preparation, and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, schizophrenia, attention deficit hyperactivity disorder, bipolar disorder, rare and orphan diseases, and sleep disorders. The subject compounds have the structure of formula (I) with the substituents being described herein.